Marvin 08021212102D 28 30 0 0 1 0 999 V2000 9.0625 -4.4716 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 9.0625 -5.2966 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 9.7637 -5.7091 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 10.5062 -5.2966 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 10.5062 -4.4716 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 9.7637 -4.0591 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 11.2900 -5.5441 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 11.7437 -4.8841 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 11.2900 -4.2241 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 9.7637 -6.5341 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 9.1037 -7.0291 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 9.3512 -7.8129 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 10.1762 -7.8129 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 10.4650 -7.0291 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 7.9487 -7.8129 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 8.6500 -8.2254 0.0000 C 0 0 2 0 0 0 0 0 0 0 0 0 8.6500 -9.0504 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 7.9487 -6.9879 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 7.9487 -6.1629 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 7.9900 -9.5454 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 8.2375 -10.3291 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 9.0625 -10.3291 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 9.3100 -9.5454 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 12.1975 -7.4829 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 13.0225 -7.4829 0.0000 P 0 0 0 0 0 0 0 0 0 0 0 0 13.8475 -7.4829 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 13.0225 -6.6579 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 13.0225 -8.3079 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 1 2 2 0 0 0 0 2 3 1 0 0 0 0 3 4 2 0 0 0 0 4 5 1 0 0 0 0 5 6 2 0 0 0 0 1 6 1 0 0 0 0 4 7 1 0 0 0 0 7 8 2 0 0 0 0 8 9 1 0 0 0 0 5 9 1 0 0 0 0 3 10 1 0 0 0 0 10 11 2 0 0 0 0 11 12 1 0 0 0 0 12 13 1 0 0 0 0 13 14 2 0 0 0 0 10 14 1 0 0 0 0 15 16 1 0 0 0 0 16 12 1 0 0 0 0 16 17 1 1 0 0 0 15 18 1 0 0 0 0 18 19 3 0 0 0 0 17 20 1 0 0 0 0 20 21 1 0 0 0 0 21 22 1 0 0 0 0 22 23 1 0 0 0 0 17 23 1 0 0 0 0 24 25 1 0 0 0 0 25 26 1 0 0 0 0 25 27 2 0 0 0 0 25 28 1 0 0 0 0 M END > CHEBI:66917 > ruxolitinib phosphate > A phosphate salt obtained by reaction ruxolitinib with one equivalent of phosphoric acid. Used for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. > 3 > (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate > Jakafi > C17H21N6O4P; C17H18N6.H3PO4 > 404.36020 > 404.13619 > 0 > OP(O)(O)=O.N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 > InChI=1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1 > JFMWPOCYMYGEDM-XFULWGLBSA-N > 1092939-17-7 > 18762556 > 1092939-17-7 > D09960 > 22209716; 22469651; 22474318; 22544377 $$$$